Skip to main content

Clogged Glymphatic System Linked to Dementia Risk

MRI scans from nearly 40,000 people revealed biomarkers linked to defective toxin clearance in the brain predicted the susceptibility to dementia later in life.

Written byRJ Mackenzie
| 2 min read
Cropped view of senior man playing with puzzles, indicative of dementia risk.
Register for free to listen to this article
Listen with Speechify
0:00
2:00

The brain’s built-in clearance system, called the glymphatic system, removes toxins from the brain through the flow of cerebrospinal fluid (CSF) via minuscule channels that trace blood vessels. Scientists have suspected that the glymphatic system may play a role in processes such as sleep and recovery from traumatic brain injury.

Now, researchers led by Hugh Markus, a neurologist at the University of Cambridge, used data from the massive UK Biobank resource and found a link between reduced glymphatic function and increased risk of dementia. Their findings, published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, highlight why impaired cardiovascular function—which is closely tied with the glymphatic system—and poor sleep associate with dementia risk.1

The Challenge of Studying the Brain’s Waste System

Researchers have suspected that reduced glymphatic flow—and consequently, reduced waste clearance—plays a role in the development of dementias like Alzheimer’s disease, wherein toxic protein plaques accumulate in the brain.2 But much of the research to support this theory came from animal models, where scientists could invasively analyze CSF movement.

However, with advances in imaging technology, researchers proposed that data mined from magnetic resonance imaging (MRI) scans of the brain could indicate glymphatic function. Previous studies have examined some of these data, but only in small samples.3

Continue reading below...

Like this story? Sign up for FREE Newsletter updates:

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter content
Subscribe

Markus and his team examined MRI data from the longitudinal UK Biobank cohort, using a sample size of tens of thousands of scans. Machine learning algorithms pioneered by study co-author Yutong Chen, who worked on the project during his medical degree, were key to unlocking this data resource.

Identifying Glymphatic Biomarkers

The team found that three biomarkers linked to impairments in glymphatic function predicted dementia onset in the following ten years. These were CSF velocity as it flowed into the brain, the volume of the choroid plexus (a blood vessel network that produces CSF), and a measure of water diffusion along the brain’s perivascular spaces.

The team expressed guarded optimism about their findings. “Although we have to be cautious about indirect markers, our work provides good evidence in a very large cohort that disruption of the glymphatic system plays a role in dementia. This is exciting because it allows to ask: How can we improve this?” said Chen in a press release.

The glymphatic system is closely tied to the brain’s vascular system. Damage to small blood vessels and dysfunction in blood flow in the brain exacerbates dementia symptoms. According to the team, their results suggest glymphatic disruption mediates this effect.

Further, they suggested that treatments to improve the function of the glymphatic system or vascular risk factors like high blood pressure, which can damage blood vessels, could produce long-term reductions in dementia risk.

“At least a quarter of all dementia risk is accounted for by common risk factors like blood pressure and smoking. If these impair glymphatic function, then we can intervene. Treating high blood pressure or encouraging people to stop smoking would be an achievable way to helping the glymphatic system work better,” Markus said in the press release.

Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • RJ Mackenzie

    RJ is a freelance science writer based in Glasgow. He covers biological and biomedical science, with a focus on the complexities and curiosities of the brain and emerging AI technologies. RJ was a science writer at Technology Networks for six years, where he also worked on the site’s SEO and editorial AI strategies. He created the site’s podcast, Opinionated Science, in 2020. RJ has a Master’s degree in Clinical Neurosciences from the University of Cambridge.

    View Full Profile

Related Topics

You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
The Scientist October Digest cover
October 2026

Antarctica’s Blood Falls Teems With Mysterious Microbial Life

Miles away from the closest ocean, marine microbes thrive in the red ice and mud around Blood Falls, offering clues to microbial adaptation and past climate events.

View this Issue
Evaluating Blood Biomarkers for Alzheimer’s Disease Staging

Evaluating Blood Biomarkers for Alzheimer’s Disease Staging

​Beckman Coulter
Find better biologics faster with Stunner and the AI Developability Workcell

Find better biologics faster with Stunner and the AI Developability Workcell

Unchained Labs
An image of microcentrifuge tubes arranged within colorful laboratory racks.

Choose clarity. Choose speed. Choose MyMass™

Refeyn
Characterizing LNP Heterogeneity With Super-Resolution Imaging

Characterizing LNP Heterogeneity With Super-Resolution Imaging

Oni

Products

Stellaromics Logo

Stellaromics Expands Pyxa Adoption as Instruments are Installed at Leading Research Institutions Across the U.S. and EuropeStellaromics, Inc., the leader in 3D

A monoclonal antibody surrounded by immune cells and red blood cells

CellRaft AIR: Find the Right Antibody-Producing Cells Faster

Cell Microsystems
Maxwell® Rapid ccfDNA Kit

Maxwell® Rapid ccfDNA Kit: Automated Purification of ccfDNA in Under 30 Minutes

Promega
Leica Biosystems, Tempus, and Paige logos side by side, marking the addition of Paige digital pathology AI tools to the Aperio AI Store.

Oncology Researchers Gain AI Cancer Tools in One Platform